Premium
Prenatal screening for cystic fibrosis: an economic analysis
Author(s) -
Nielsen Randi,
GyrdHansen Dorte
Publication year - 2002
Publication title -
health economics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.55
H-Index - 109
eISSN - 1099-1050
pISSN - 1057-9230
DOI - 10.1002/hec.652
Subject(s) - cystic fibrosis , medicine , newborn screening , pound (networking) , population , prenatal screening , danish , pediatrics , fetus , prenatal diagnosis , pregnancy , environmental health , biology , world wide web , computer science , genetics , linguistics , philosophy
Cystic fibrosis (CF) is the most common life‐shortening genetically transmitted disease in Denmark with a birth prevalence of 1 in 4700, resulting in 12–15 new cases of cystic fibroses annually. The aim of this study is to disclose the societal resource implications of introducing a population wide prenatal screening programme for cystic fibrosis in Denmark. The present analysis is limited to the monetary consequences of introducing a screening programme, where costs of screening are compared to the potential benefits measured in cost savings involved if births of CF patients are avoided. Screening costs in a Danish setting were estimated at DKK 2 771 262 (£231 438) per aborted affected fetus in the first screening round, stabilising at DKK 1 864 594 (£155 383) per aborted affected fetus at subsequent screening rounds. Comparing this figure with the estimated benefits of avoiding a CF case (DKK 2.1–4.4 million; £175 000–366 667) suggests that introducing a screening programme for cystic fibrosis will be net cost saving irrespective of the perspective of the analysis, assumptions on replacement children and method of estimating long‐term production gains/losses. Copyright © 2001 John Wiley & Sons, Ltd.